Genetic discovery shows racial differences a factor in mortality in heart attack patients on anti-clotting drug

June 18, 2014 by Kristina Sauerwein, Washington University School of Medicine in St. Louis
Genetic find shows racial differences a factor in mortality in heart attack patients on anti-clotting drug
Cardiologist Sharon Cresci, MD, led a genetic study showing that racial differences account for a higher risk of mortality in some patients taking clopidogrel (Plavix) after a heart attack. Credit: Robert Boston

(Medical Xpress)—Researchers have identified the first genetic variations linked to race that begin to explain a higher risk of death among some African American and Caucasian patients taking the anti-clotting drug clopidogrel (Plavix) after a heart attack.

These variants increased patients' risk of dying in the year following a first , but they appeared to do so for different reasons depending on race, according to a study at Washington University School of Medicine in St. Louis.

In particular, the team found that two DNA variants common in African Americans were associated with an increased risk of both bleeding and death. In Caucasians, a different variant was linked to additional heart attacks and a higher risk of death.

The research is published June 17 in the American Heart Association journal Circulation: Cardiovascular Genetics.

The variations influence the way people metabolize clopidogrel and can alter its effectiveness. The blood-thinning drug commonly is prescribed after a heart attack to reduce the likelihood of another heart attack or a stroke.

"The research is provocative," said the study's first author, cardiologist Sharon Cresci, MD, assistant professor of medicine and of genetics. "Knowing about potential genetic differences based on race can help physicians tailor drugs to patients based on their genetic makeup."

Clopidogrel is metabolized in the liver, where it is turned into its active form via a group of enzymes called cytochrome P450, or CYP for short. Although clopidogrel is effective in many patients, earlier studies determined that some people metabolize the drug better than others.

Indeed, in 2010, the Food and Drug Administration added a "black box" warning to labels of clopidogrel after research that primarily involved Caucasians showed that people with a particular CYP genetic variant metabolized the drug poorly, which reduced the amount of the drug circulating in the blood. These patients had a higher risk of heart attack and stroke.

Additional studies showed that other CYP gene variants are linked to the rapid metabolism of clopidogrel and that patients with those variants had a higher risk of bleeding.

But it has not been clear until now that the effects of these particular gene variations can vary by race in patients taking clopidogrel after a heart attack.

For the study, the researchers analyzed CYP variants among 2,062 Caucasians and 670 African Americans who suffered heart attacks. Nearly 80 percent of the Caucasians and 65 percent of the African Americans were prescribed clopidogrel. The patients were enrolled in a major study known as TRIUMPH (Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health) conducted from 2005 to 2008 at 24 U.S. hospitals, including Barnes-Jewish Hospital in St. Louis.

Among patients taking clopidogrel, the one-year mortality rate for African Americans was 7.2 percent, compared with 3.6 percent for Caucasians.

Caucasians who carried the CYP2C19*2 variant, which has been linked to poor metabolism of the drug, had a higher rate of repeat heart attacks and death. The higher rate of heart attacks is consistent with the slower metabolism of clopidogrel.

However, among African Americans treated with clopidogrel, the CYP2C19*2 variant was not associated with a higher rate of death.

Rather, African Americans had higher rates of bleeding and death if they carried either of two other variants: CYP1A2*1C or CYP2C19*17, the latter of which has been associated with the rapid metabolism of clopidogrel. Among Caucasians on clopidogrel, neither variant increased the risk of death.

"This is very novel information that begs for more research," said cardiologist Richard G. Bach, MD, the study's senior author and an associate professor of medicine at Washington University.

Although genetic testing is available to identify CYP variants in a patient's DNA, these tests generally are not widely used by cardiologists. Results of the current study suggest this practice may need to be reconsidered.

"This research is an important addition to the field because previous studies looking at CYP gene variants and their effects on risks of repeat heart attacks, bleeding and death have included predominantly Caucasian patients of European ancestry," Cresci noted. "There is almost no data, until now, about these variants in African Americans."

Research examining how genetic variants alter the effectiveness of remains somewhat controversial, Bach said. Many physicians feel that before they can tailor medical therapy for , more data is needed to prove there is a clear link between genetic variants and negative health consequences and that tailoring therapy will improve patients' outcomes, he explained.

His hope is that additional research would provide more definitive conclusions to help physicians choose the best medications for patients after a heart attack and, ultimately, "to reduce the too-high rate of death and disability for after a heart attack," Bach said.

Cresci agreed, adding: "By focusing on genetic differences, we may be able to individualize therapies after heart attacks and achieve the best treatment for each patient."

Explore further: Taking prescribed anti-clotting drug may help save stent patients' lives

More information: Cresci S, Depta JP, Lenzini PA, Li AY, Lanfear DE, Province MA, Spertus JA and Bach RG. "Cytochrome P450 gene variants, race and mortality among clopidogrel-treated patients following acute myocardial infarction." Circulation: Cardiovascular Genetics. In print, June 17, 2014.

Related Stories

Taking prescribed anti-clotting drug may help save stent patients' lives

May 28, 2014
If you've just received a coronary artery stent to prop open a blood vessel, your life may depend on filling your prescription and taking an anti-clotting drug within days of leaving the hospital, according to a large study ...

Heart attack drug proven to have no rebound effect

February 3, 2014
(Medical Xpress)—Clopidogrel, a drug prescribed to thousands of people who have had a heart attack, can be safely withdrawn with no 'rebound effect', according to a study by Aberdeen scientists.

Increased risk of bleeding with combined use of SSRIs and antiplatelet therapy after heart attacks

September 26, 2011
Heart attack patients taking selective serotonin reuptake inhibitors (SSRIs) in combination with antiplatelet therapy -- acetylsalicylic acid (ASA), clopidogrel or both (dual antiplatelet therapy) -- are at higher risk of ...

Genetic test for Plavix use may be unneeded: study

December 29, 2011
A new study published Wednesday cast doubt on the usefulness of a genetic test for patients taking the anti-coagulant drug Plavix, calling into question last year's FDA warning about the blood thinner.

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.